NanoViricides, Inc. (NYSE:NNVC – Get Free Report) was the recipient of a significant decline in short interest in September. As of September 30th, there was short interest totaling 58,700 shares, a decline of 74.7% from the September 15th total of 231,900 shares. Based on an average trading volume of 180,400 shares, the days-to-cover ratio is currently 0.3 days. Based on an average trading volume of 180,400 shares, the days-to-cover ratio is currently 0.3 days.
NanoViricides Stock Performance
NNVC stock opened at $1.50 on Friday. The firm has a market cap of $26.15 million, a price-to-earnings ratio of -2.08 and a beta of 1.16. NanoViricides has a one year low of $0.94 and a one year high of $1.92. The firm has a 50-day simple moving average of $1.44 and a two-hundred day simple moving average of $1.43.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in NanoViricides stock. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of NanoViricides, Inc. (NYSE:NNVC – Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 22,138 shares of the company’s stock, valued at approximately $26,000. Wealth Enhancement Advisory Services LLC owned 0.14% of NanoViricides as of its most recent filing with the Securities & Exchange Commission. 10.30% of the stock is currently owned by institutional investors and hedge funds.
NanoViricides Company Profile
NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.
Read More
- Five stocks we like better than NanoViricides
- Earnings Per Share Calculator: How to Calculate EPS
- Johnson & Johnson’s M&A Strategy Is the Real Story for Investors
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Tesla: Some Analysts Are Calling for A 30% Drop—Time to Panic?
- How to Plot Fibonacci Price Inflection Levels
- Hedge Funds Flip on the Dollar—A Buy Signal for These 3 Stocks?
Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.
